Skip to content

Effect of folic acid in Buerger`s disease

Evaluation of effect of folic acid in Buerger`s disease on homo cysteine and clinical status

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201108012106N2
Enrollment
30
Registered
2011-08-04
Start date
2004-01-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Buerger`s disease. Thromboangiitis obliterans [Buerger]

Interventions

Intervention 1: Intervention group will take tab. Folic acid 5 mg per day, for 6 month. Intervention 2: Control group will take placebo(the same color, size, box to tab Folic acid 5 mg) one tablet per
Treatment - Drugs
Placebo
Intervention group will take tab. Folic acid 5 mg per day, for 6 month
Control group will take placebo(the same color, size, box to tab Folic acid 5 mg) one tablet per day for 6 month

Sponsors

Applied Physiology Research Center
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Inclusion criteria: Buerger`s patients referring to Alzahra hospital who have consent of participation to study; history of smoking; onset of disease before 50 year-old; upper limb involvement or phlebitis migrants; obliterative arterial disease below popliteal artery and no risk factor of atherosclerosis except smoking; no history of hypertension, diabetes mellitus, ischemic heart disease, cerebrovascular disease or collagen vascular disease. Exclusion criteria: surgical (sympathectomy or vascular bypass) or medical (Illeoprost or corticosteroid) changes in treatment; starting Aspirin, calcium channel blocker, VitB6 or VitB12 or stop smoking during the study; drug incompliance during the study and not willing to continue the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Scale of wound. Timepoint: At the beginnig and 2nd and 6th months. Method of measurement: Wagner Scale.

Secondary

MeasureTime frame
Homocysteine. Timepoint: At the beginnig and 2nd and 6th months. Method of measurement: Lab test.;Scale of pain. Timepoint: At the beginnig and 2nd and 6th months. Method of measurement: VAS.;Anticardiolipin. Timepoint: At the beginnig and 2nd and 6th months. Method of measurement: Lab test.;Size of wound. Timepoint: At the beginnig and 2nd and 6th months. Method of measurement: Millimeter.;Number of steps walkingwithout pain. Timepoint: At the beginnig and 2nd and 6th months. Method of measurement: Number.;Sense of patient about healing. Timepoint: At the 2nd and 6th months. Method of measurement: Ask a patient.;Minor amputation. Timepoint: At the beginnig and 2nd and 6th months. Method of measurement: Number.;Major amputation. Timepoint: At the beginnig and 2nd and 6th months. Method of measurement: Number.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAfrooz Eshaghian

Applied Physiology Research Center

eshaghian@edc.mui.ac.ir+98 31 1236 7247

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026